1. Tolerability and Efficacy of Almotriptan in the Long-Term Treatment of Migraine
- Author
-
X. Segarra, A. Prusinski, J. Pascual, P. Ferrer, J. Jelencsik, RM Falk, X. Cabarrocas, R. Docekal, and X. Luria
- Subjects
Adult ,Male ,Indoles ,Adolescent ,Migraine Disorders ,medicine.medical_treatment ,Administration, Oral ,Self Administration ,Chest pain ,Time ,Almotriptan ,medicine ,Humans ,Adverse effect ,Aged ,Pain Measurement ,Chemotherapy ,business.industry ,Vascular disease ,Incidence (epidemiology) ,Middle Aged ,medicine.disease ,Tryptamines ,Serotonin Receptor Agonists ,Treatment Outcome ,Neurology ,Tolerability ,Migraine ,Anesthesia ,Female ,Neurology (clinical) ,medicine.symptom ,business ,Tablets ,medicine.drug - Abstract
Background: Almotriptan is a highly specific 5-HT1B/1D receptor agonist, which acts selectively on blood vessels of the brain. Short-term studies have demonstrated that almotriptan provides rapid, effective and reliable relief of migraine attacks, while offering excellent tolerability. Purpose: To assess the long-term tolerability and efficacy of oral almotriptan 12.5 mg administered for every migraine attack over a 1-year period. Methods: A total of 762 patients treated 13,751 attacks (1–97 per patient); 61.5% of attacks were treated with one 12.5-mg dose, while for 38.5% of attacks, patients took a second dose within 24 h. Results: Three hundred and ninety-one patients (51.3%) experienced a total of 1,617 adverse events (AEs). The majority (88.6%) of AEs were of mild-to-moderate intensity, and only 28.8% of AEs were considered to be related to the study drug. Only 2 patients experienced serious AEs possibly related to almotriptan, syncope and chest pain; both recovered without any sequelae. Patients reported at least 1 AE in 11% of attacks treated. The incidence of AEs decreased during the study. Only 6 (0.8%) study withdrawals were due to AEs considered to be related to almotriptan. Tolerability was not compromised in patients taking 2 doses of almotriptan or in those using migraine prophylactics. Patient age or sex did not influence the incidence of AEs. There was no evidence of tachyphylaxis in those patients completing the study. Pain relief at 2 h after the initial dose was achieved in 84.2% of moderate/severe attacks. Patients were pain free at 2 h after dose in 58.2% of all attacks. Older patients (>40 years) tended to respond better than younger ones (Conclusion: This large, open study indicates that the new, specific 5-HT1B/1D agonist almotriptan, at a dose of 12.5 mg, is a well tolerated and effective treatment for migraine pain when used over a period of up to 1 year.
- Published
- 2001
- Full Text
- View/download PDF